The parameters for calculating the burden of schizophrenia in Thailand

Main Article Content

Patanon Kwansanit
Manit Srisurapanont


          Objective  To review and evaluate the parameters needed for the calculation of burden of schizophrenia in Thailand.
          Material and method  A review utilizing data from PubMed, Embase and PsycINFO using specific keywords to extract relevant data and parameters was done. The selected studies were published between 1990-2017, in both English and Thai. The abstracts were screened, and the full text papers were systematically reviewed and synthesizing according to each subtopic.
          Results  Lifetime and one-month prevalence of schizophrenia in Thailand in 2013 was 0.7% and 0.6% for acute and residual phase respectively. The trend of prevalence is stable and slightly decreased since the first survey in 1998. The severity distribution for the acute phase was 63%, and the residual phase was 37%. The age of onset was 20 years old in male and 24 years old in female. The disability duration until remission was 15.62±11.1 years and 8.28±8.51 years in treatment and un-treatment groups respectively. The relapse rate for second and third episode within five years was 81.9% (95% CI; 70.6-93.2), and 78.0% (95% CI; 46.5-100.0) and remission rate was 1.37. The relative risk of mortality (RRM) was 1.1. The disability weight was 0.756 (0.571-0.894) for acute and 0.576
(0.399-0.756) residual phase, respectively.
          Conclusion  Appropriate parameter for estimation of the burden of schizophrenia in Thailand is the current prevalence. More studies are needed to evaluate other epidemiological parameters that have not been studied in Thailand, i.e. age of onset, duration of illness, relapse and remission rate and the
disability weight which are specific to Thailand.


Download data is not yet available.

Article Details

Review article


1. Mathers CD, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, et al. Global burden of disease 2000: Version 2 methods and results. Geneva: World Health Organization; 2002.
2. McFarlane WR. Prevention of the first episode of psychosis. Psychiatr Clin North Am 2011;34:95-107.
3. Ayuso-Mateos JL. Global burden of schizophrenia in the year 2000-version 1 estimates. Geneva: World Health Organization; 2002.
4. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 2013;382:1575-86.
5. Burden of disease Thailand working group. Disability – adjusted life yeas (DALYs) 2014. Nonthaburi: International
Health Policy Program, Ministry of Public Health; 2017. (in Thai)
6. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;6:274-85.
7. Kittirattanapaiboon P, Tantirangsee N, Chutha W, Tanaree A, Kwansanit P, Assanangkornchai S. Prevalence of mental disorders and mental health problems: Thai national mental health survey 2013. Journal of Mental Health of Thailand 2017;25:1–19. (in Thai)
8. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PloS ONE 2015;10:e0116820.
9. Phanthunane P, Vos Theo, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr 2010;8:24. doi:10.1186/1478-7954-8-24.
10. Sadock BJ, Sadock VA. Kaplan and Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Philadelphia: Lippincott Williams & Wilkins; 2011.
11. Buoli M, Caldiroli A, Panza G, Altamura AC. Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig 2012;9:354-60. doi: 10.4306/pi.2012.9.4.354.
12. Saha S, Barendregt JJ, Vos T, Whiteford H, McGrath J. Modelling disease frequency measures in schizophrenia
epidemiology. Schizophr Res 2008;1:246-54.
13. AlAqeel B, Margolese HC. Remission in schizophrenia: critical and systematic review. Harv Rev Psychiatry 2013;6:281-97.
14. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;3:241-7.
15. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality.
Epidemiol Rev 2008;1:67-76.
16. Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic
disorders with measures of substance use. JAMA Psychiatry 2014;3:248–54.
17. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from
diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.
18. Kessler RC, Ustün TB. The World Mental Health (WMH) survey initiative version of the World Health Organization
(WHO) Composite International Diagnostic Interview (CIDI). Int K Methods Psychiatr Res 2004;13:93-121.
19. Suraaroonsamrit B, Panyayong B. The development of mental health and psychiatric service in health areas.
Journal of Mental Health of Thailand 2014;3:142-56. (in Thai)
20. Simon AE, Cattapan-Ludewig K, Zmilacher S, Arbach D, Gruber K, Dvorsky DN, et al. Cognitive functioning in the
schizophrenia prodrome. Schizophr Bull 2007;3:761-71.
21. De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007;1:68-73.
22. World Health Organization (WHO). Schizophrenia: an international follow-up study. Chichester: Wiley; 1979.
23. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia:
proposed criteria and rationale for consensus. Am J Psychiatry 2005;3:441-9.
24. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai
schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007;1:14.